干扰素联合放化相伴治疗晚期非小细胞肺癌患者的疗效及对免疫功能的影响

摘要

目的 探讨放化相伴治疗联合干扰素对晚期非小细胞肺癌(NSCLC)患者的近期疗效,以及对患者免疫功能的影响.方法 选取2016年3月至2017年2月在本院住院期间晚期NSCLC患者83例,按照随机数表法分为两组,对照组应用放化相伴治疗,观察组在此基础上联合应用干扰素(PEG-INF-α),观察并记录所有患者治疗前后生存质量、T细胞亚群水平,同时对比两组患者不良反应发生状况.结果 观察组疾病控制率为88.09％,对照组的疾病控制率为65.85％,两组比较差异有统计学意义(P<0.05);两组患者治疗前T淋巴细胞亚群CD3+、CD4+、CD4+/CD8+、CD8+及NK细胞水平差异不显著(P>0.05),治疗后,两组患者的CD3+、CD4+、CD4+/CD8+、CD8+、NK百分比:观察组(60.12±7.27,36.67±4.78,25.64±5.06,1.41±0.49,19.97±9.79)％;对照组(56.71±6.83,31.47±4.28,30.02±4.86,1.13±0.33,18.47±9.75)％,CD3+、CD4+、CD4+/CD8+百分数对比差异显著(P<0.05).结论 放化相伴联合干扰素治疗NSCLC可显著提高临床疗效,降低不良反应发生率,并显著提高机体免疫功能,可在临床推广.%Objective To investigate the short-term efficacy of chemoradiotherapy plus interferon in patients with advanced non-small cell lung cancer and its influence on immune function. Methods From February 2016 to February 2017, 83 advanced NSCLC patients in our hospital were randomly divided into two groups, the control group and observation group. The control group was treated with chemoradiotherapy, and the observation group was treated with interferon PEG-INF-αon this basis. The quality of life and the level of T lymphocyte subsets were observed and recorded before and after treatment, and the adverse reactions were compared between the two groups. Results The disease control rate of the observation group was 88. 09％, and 65. 85％ in the control group (P<0. 05). T lymphocyte subsets CD3+, CD4+, CD4+/CD8+, CD8+ and NK cell levels showed no statistical significance between the two groups ( P>0. 05) before treatment. After treatment, the percentage of CD3+, CD4+, CD4+/CD8+, CD8+ and NK was (60. 12 ± 7. 27), (36. 67 ± 4. 78), (25. 64 ± 5. 06), (1. 41 ± 0. 49), (19. 97 ± 9. 79) ％ in the observation group, and (56. 71 ± 6. 83), (31. 47 ± 4. 28), (30. 02 ± 4. 86), (1. 13 ± 0. 33), (18. 47 ± 9. 75) ％ in the control group. The percenta-ges of CD3+, CD4+ and CD4+/CD8+ in the two groups were statistically significant (P<0. 05). Conclusion Chemora-diotherapy combined with interferon in treatment of non-small cell lung cancer can significantly improve the clinical effi-cacy, reduce the incidence of adverse reactions, and improve their immune function, which can be popularized in clini-cal practice.